

**2013**

**Screening von ausgewählten zeckenübertragbaren Infektionen, *Borrelia species sensu lato*, *Anaplasma phagocytophilum* und *Rickettsia helvetica* bei Blutspendern und Militärpersonen in der Schweiz – eine bevölkerungsweite, prospektive Querschnittsstudie**  
Aliyev E, Hatz C, Mutsch M. Studiengruppe **Tinguely C, Schmid S, Satz N, Bankoul S, Jamnicki B, Bopp M, Peter O, Lienhard R, Niederhauser C, Fontana S, Steffen R, Frey F, Strasser M, Engler O.** Swiss Public Health Conference 2013, 15.-16.08.2013, Zürich.

**Novel KEL Heterozygous Mutations Associated with Apparent Lack of Kell Antigens KEL1 AND KEL2 in Two Patients**

Karamatic Crew V, Thornton N, Murton NM, **Lejon Crottet S, Hustinx H, Daniels G.** Transfusion Medicine 2013;23,Suppl.2:1-29.

**Multicenter study of a new highly sensitive and specific HIV antigen/antibody combo assay, Enzygnost HIV Integral 4**

Weik M, Dengler T, Eberle J, Gürler L, Karl A, Korn K, Scheiblauer H, **Tinguely C, Wolf E, Stangl A.** Vox Sanguinis 2013;105,Suppl.1:65-299.

**Six years of serological *Plasmodium* spp. antibody screening in Swiss blood donors**  
**Tinguely C, Humbel TH, Gottschalk J, Thierbach J, Fontana S, Niederhauser C.** Vox Sanguinis 2013;105,Suppl.1:65-299.

**A long PCR system for the investigation of difficult Rhesus variants**  
**Aeschlimann J, Gowland P, Graber J, Hustinx H, Fontana S, Niederhauser C.** Vox Sanguinis 2013;105,Suppl.1:65-299.

**Evaluation of Plasmapheresis performed by Autopheresis C and Trima Accel from a donor, product, operator, and regulator perspective**

Räber C, Ayer I, Kaufmann T, **Tschaggelar A, Fontana S.** Transfus Med Hemother 2013;40(suppl1):1-90.

**Mixed field agglutination in weak D type 31: No Rh complex alteration except for diminished Band3**

Reif J, **Hustinx H, Dauber EM, Körmöczi G.** Transfus Med Hemother 2013;40(suppl1):1-90.

**Investigation of RHCE\*ceJAL in a Southern US Black Population**

Moulds JM, Billingsley KL, Noumsi GT, **Gowland P.** Transfusion 2013;53(suppl.S2):219-278A.

**2012**

**Novel ABO alleles expresing A<sub>w</sub> and B<sub>w</sub> phenotypes.**

Hult AK, Hellberg A, Storry JR, Jorgensen R, Peyrard T, **Hustinx H, Olsson ML.** Transfusion. 2012; Vol52 Suppl3: 41A S72-030L.

**The Swiss Approach for HBV Safety in Blood Donors.**

**Niederhauser C, Tinguely C, Fontana S, Stoltz M.** Transfusion Medicine and Hemotherapy. 2012;39(Suppl1):10 OS5.04.

**Enzygnost Anti-HCV 4.0 EIA, a Step Forward in HCV Diagnostics.**

**Tinguely C, Hotz M, Schmandt W, Kehl T, Stangl A, Niederhauser C.** Transfusion Medicine and Hemotherapy. 2012;39(Suppl1):42 P3.18.

**Which HBV DNA sensitivity limit is required for the Swiss Blood Donor population.**

**Niederhauser C, Tinguely C, Fontana S, Stolz M.** VoxSanguinis. 2012;Vol103(Suppl1):64 6A-S49-04.

**Output of High Yield Platelet (PLT) Apheresis before and after pathogen reduction with amotosalen and UVA: triple dose PLT are challenging, but still up-to-date.**

**Fontana S.** VoxSanguinis. 2012;Vol103(Suppl1):142 P-238.

**Serological screening for Chagas disease in Swiss Blood Donors.**

**Tinguely C, Canellini G, Waldvogel S, Fontana S, Niederhauser C.** VoxSanguinis. 2012;Vol103(Suppl1):181 P-359.

**Novel *KEL* heterozygous mutations associated with weakening of Kell antigens Kel1 and Kel2.**

Karamatic Crew V, Poole J, Burton N, **Hustinx H, Aznar R, Moule R, Stamps R, Madden P, Daniels G.** VoxSanguinis. 2012;Vol103(Suppl1):210 P-451.

**Introduction of an validated in-house high throughput blood group genotyping system into a routine setting.**

**Lejon Crottet S, Gowland P, Hustinx H, Fontana S, Stolz M, Niederhauser C.** VoxSanguinis. 2012;Vol103(Suppl1):216 P-471.

**A new approach for transfusing patients in Switzerland.**

**Hustinx H, Niederhauser C, Lejon Crottet S, Gowland P, Vogt M, Mansouri Taleghani B, Fontana S.** VoxSanguinis. 2012;Vol103(Suppl1):249 P-585.

**Seroprevalence of antibodies to *Borrelia burgdorferi* in a healthy Swiss blood donor and military staff population.**

**Tinguely C, Engler O, Niederhauser C, Aliyev E, Fontana S, Strasser AM, Bankoul S, Tschaggelar A, Mütsch M.** SSM Annual Meeting. 2012; 20.

**A Transfusion-transmitted HBV Infection in Newborns.**

**Niederhauser C, Weingand T, Maier A, Tinguely C, Fontana S, Stolz M.** SSM Annual Meeting. 2012; 47 P65.

**Evolution of the HBV diagnostic safety in Swiss blood products.**

**Niederhauser C, Tinguely C, Fontana S, Stolz M.** SSM Annual Meeting. 2012; 49 P79.

**High-throughput blood group genotyping (HTBGG) shows an unexpected high frequency of FY\*X.**

**Gowland P, Lejon Crottet S, Henny C, Still F, Niederhauser C, Fontana S.** Clin.Lab. 2012;58(7-8): S5-S6.

**2011**

**Seroprevalence of antibodies to Borrelia burgdorferi in a healthy Swiss blood donor population.**

**Tinguely C, Engler O, Niederhauser C, Fontana S, Tschaggelar A, Strasser M, Mütsch M.**  
Transfus Med Hemother. 2011;38(Suppl1):44 P2.08.

**Randomized controlled trial (RCT) comparing the transfusion efficacy of triple and double Amicus platelet concentrates collected in plasma or PAS III additive solution.**

**Fontana S, Summermatter R, Vogt M, Mauchle P, Lädrach A, Pellegrini A, Mansouri Taleghani B.** Transfus Med Hemother. 2011;38(Suppl1):61 P8.05.

**A case-control study comparing high yield platelet (PLT) apheresis with Amicus V3.11 and Trima V5.1/5.2 cell separators.**

**Siderow A, Lädrach A, Fontana S.** Transfus Med Hemother. 2011;38(suppl1):61 P8.06.

**Development and Validation of an In-house High-throughput Blood Group Genotyping System.**

**Lejon Crottet S, Gowland P, Hustinx H, Fontana S, Niederhauser C.** Pipette.2011;Nr.4:14 Vortrag3.

**Swiss Rare Donor File: a cost-effective strategy for identifying Vel and KEL\*04 (Kp(b)) negative donors.**

**Hustinx H, Münger E, Fontana S, Lejon Crottet S, Gowland P, Niederhauser C.** Pipette.2011;Nr.4:16 Poster2.

**Feasibility of triple platelet (PLT) apheresis donations with the intercept pathogen reduction system.**

**Fontana S, Pellegrini A, Summermatter R, Byland C.** Vox Sanguinis. 2011;Vol.101 Suppl1:185 P-265.

**Transfusion-transmitted HBV infection of newborns through HBV contaminated RBC.**

**Niederhauser C, Weingand T, Candotti D, Meier A, Tinguely C, Allain JP, Stolz M.** Vox Sanguinis. 2011;Vol.101 Suppl1:211 P-328.

**A serological and molecular screen for WRA antigen-positive blood donors in Switzerland.**

**Gowland P, Lejon S, Niederhauser C, Fontana S, Hustinx H.** Vox Sanguinis. 2011;Vol.101 Suppl1:261 P-456.

**Comparison of the transfusion efficacy of multiple dose platelet concentrates collected in plasma or PAS III additive solution.**

**Fontana S, Summermatter R, Vogt M, Lädrach A, Mauchle P, Pellegrini A, Mansouri Taleghani B.** SMF Swiss Medical Forum. 2011;11(18:Suppl.55,93S P475. | Vox Sanguinis. 2011;Vol.101 Suppl1:135 P-142.

**Suivi de la collecte de doses définies de plaquettes lors d'une étude clinique d'efficacité transfusionnelle.**

**Fontana S, Summermatter R, Gerber R, Mauchle P, Pellegrini A, Barmettler D, Aegeuter P and Payrat JM.** Transfusion Clinique et Biologique, 25<sup>ème</sup> Congrès national de la SFTS Lyon. 2011;Vol.18-N3;P029: 346.

**Fréquence de l'allèle Kidd null suisse est plus élevée que prévu – un hot spot ?**

**Lejon S, Hustinx H, Fontana S, Niederhauser C and Gowland P.** Transfusion Clinique et Biologique, 25<sup>ème</sup> Congrès national de la SFTS Lyon. 2011;Vol.18-N3;P089: 360.

**Perte des antigènes Cromer et apparition d'un anticorps anti-IFC après transfusion et septicémie.**

**Fontana S, Cerdan P, Siegenthaler M, Niederhauser C, Passweg J, Ritz M and Hustinx H.** Transfusion Clinique et Biologique, 25<sup>ème</sup> Congrès national de la SFTS Lyon. 2011;Vol.18-N3;P116: 368.

**2010**

**An evaluation of preventive measures to reduce the risk of Trali after transfusion of single donor apheresis platelets in Switzerland.**

**Fontana S, Thierbach J, Muriset M, Sigle J, Gowland P, Niederhauser C, Sunic K, Infanti L, and Buser A.** Transfusion and Apheresis Science. 2010; 43 (suppl. 1) S13: 17.

**DARA, a new DAR variant – serologic and molecular differences between DARA, weak D type 4.2.2, DV type 7, DARE and DAR.**

Lejon S, Gowland P, Fontana S, Niederhauser C and Hustinx H. Transfusion and Apheresis Science. 2010; 43 (suppl. 1) S13: 23.

**First case of HIV window donation in Switzerland after 8 years of universal HIV NAT screening.**

Gottschalk J, Achermann Y, **Niederhauser C, Tinguely C, Glauser A, Lodemann P and FreyBM.** Transfusion and Apheresis Science. 2010; 43, (suppl. 1) S25: 27.

**Fatal outcome of a hepatitis B Virus transfusion-transmitted infection.**

**Niederhauser C, Weingand T, Maier A, Wuillemin WA ,Tinguely C, Gowland P and Stolz M.** Transfusion and Apheresis Science. 2010; 43, (suppl. 1) S26: 25.

**Optimizing collection quality and efficacy for high yield plateletpheresis in the planification of a clinical trial.**

**Fontana S, Summermatter R, Gerber R, Vogt M, Mansouri Taleghani B, Barmettler D, Agerter P, Payrat JM.** Vox Sanguinis. 2010; 99 (suppl. 1) P-0215: 169.

**Multicenter study of the new highly sensitive and specific Enzygnost HBSAG 6.0 assay.**

Schobel U, Dengler T, Doerr HW, Echevarria JM, Gerlich WH, Gottschalk J, Graziani M, Karl A, Schottstedt V, Wagner F, Weber B, Weik M, Weissbrich B, Willems WR and Nick S. Vox Sanguinis. 2010; 99 (suppl. 1): P-0536: 290.

**Lessons learned form Parvovirus B19 infections in Swiss Blood Donors.**

**Niederhauser C, Stolz M, Mauchle P and Fontana S.** Vox Sanguinis. 2010; 99 (suppl. 1): P-0614: 318.

**Trali-safe platelets: an evaluation of preventive measures to reduce the risk of Trali after transfusion of single donor apheresis platelets in Switzerland.**

**Fontana S, Thierbach J, Muriset M, Sigle J, Gowland P, Niederhauser C, Sunic K, Infanti L and Buser A.** Vox Sanguinis. 2010; 99 (suppl. 1): P-0999: 454.

**A novel B<sup>weak</sup> hybrid allele with a non-repeating CBF-enhancer region.**

Thuresson B, Hosseini-Maaf B, Hult AK, **Hustinx H**, Chester MA and Olsson ML. Vox Sanguinis. 2010; 99 (suppl. 1): P-0735: 362.

**Mixed field agglutination in AB0 typing after allogeneic HSCT: influence of recipient secretor status.**

Sigle JP, **Hustinx H**, Storry JR Olsson ML and Buser A. Vox Sanguinis. 2010; 99 (suppl. 1): P-0742: 365.

**Weak A phenotypes associated with novel AB0 alleles carrying the A<sup>2</sup> –related 1061C deletion and various missense amino acid substitutions.**

Hult AK, Yazer MH, Jorgensen R, Hellberg A, Palcic MM, Olsson ML, Peyrard T and **Hustinx H**. Vox Sanguinis. 99 (suppl. 1): P-0776: 377.

**Modulation of antibodies to Cromer Blood Group System antigens (anti Tcc(a)) and anti-Kidd (JKa) antibodies during late pregnancy.**

Venturelli D, Lunghi M, Baldini M, **Hustinx H**, Neri I, Mazza V and Montagnani G. Transfusion. 2010; 50 (Suppl. S2): SP264: 156A.

**Effects of a simple guideline for transfusion of red blood cells (RBC) in elective hip and knee replacement on blood supply and costs.**

**Fontana S**, Müller U, Perler M, Krummen L, Läderach A, De La Cuadra C, Luginbühl M and Mansouri Taleghani B. Swiss Medical Forum. 2010; 10 (Suppl. 50): PFM51: 19 S.

**Transfusion reaction due to coldagglutinins in a patient with Malaria.**

Sigle JP, Boldanova T, Flückiger U, Infanti L, Rüfli T, **Hustinx H** and Buser A. Swiss Medical Forum. 2010; 10 (Suppl. 50): P225:95 S.

**Trali-safe platelets: An evaluation of preventive measures to reduce the risk of Trali after transfusion of single donor apheresis platelets in Switzerland.**

**Fontana S**, Thierbach J, **Muriset M**, Sigle J, **Gowland P**, **Niederhauser C**, Sunic K, Infanti L and Buser A. Swiss Medical Forum. 2010; 10 (Suppl. 50): P226: 96 S. | TransufSION and Apheresis Science 2010;43 S1:S13.

**Fatal outcome of a Hepatitis B Virus transfusion-transmitted infection.**

**Niederhauser C**, Weingand T, Maier A, Wuillemin WA, **Tinguely C**, **Gowland P** and **Stoltz M**. Swiss Society for Microbiology: 69<sup>th</sup> Annual Assembly of the SSM. 2010; P139: 221. | Transfusion and Apheresis Science 2010;Sept:Vol43,Suppl.1,S26A25.

**Frequency and characteristics of Parvovirus B19 infections in Swiss Blood Donors.**

**Niederhauser C**, **Stoltz M**, **Mauchle P**, **Gowland P** and **Fontana S**. Swiss Society for Microbiology: 69<sup>th</sup> Annual Assembly of the SSM. 2010; P140: 222.

**A new DAR variant, DARA – serologic and molecular differences between DARA, Weak D type 4.2.2, Dv type 7, Dare and Dar.**

**Lejon S**, **Gowland P**, **Fontanan S**, **Niederhauser C** and **Hustinx H**. Transfusion Medicine. 2010; 20 (Suppl 1): S122: 12.

**A silent mutation 939g> A in RHCE (Pro313) causes loss of a splice site and complete skipping of exon 6 resulting in expression of a novel E antigen.**

Green C, Bugert P, **Hustinx H**, Daniels G and Karamatic V. Crew. Transfusion Medicine. 2010; 20 (Suppl 1): PO20: 33.

**2009**

**Dépistage d'anticorps *Plasmodium ssp* par EIA en Suisse chez des donneurs de sang**

**Tinguely C, Laeng B, Fontana S, Niederhauser C.** Transfusion Clinique et Biologique, 24<sup>ème</sup> Congrès national de la SFTS Strasbourg . 2009;Vol.16-N3;P033.

**Spontaneous Rh Phenotype Splitting: Loss of Heterozygosity on Chromosome 1 in Different Blood and Bone Marrow Cell Subsets**

Körömczi G.F, Dauber E.-M, Swoboda S, **Mansouri Taleghani B, Fontana S, Hustinx H**, Sikyr S, Colucci G, Schwarzinger I, Fritsch G, Mayr W.R. Transfusion Medicine and Hemotherapy. 2009;36 (S1):24.

**A Simple Guideline Reduces the Need for Red Blood Cell (RBC) Transfusions: A Prospective, Multicenter, Before-and-after Study in Elective Hip and Knee Replacement**

**Fontana S, Müller U, Perler M, Lädrach A, Krummen L, de la Cuadra C, Luginbühl M, Mansouri Taleghani B.** Transfusion Medicine and Hemotherapy. 2009;49 Suppl):170A.

**Red Blood Cell (RBC) Use in Elective Cardiac and Vascular Surgery: A Prospective Assessment of the Effect of a Transfusion Guideline in a Swiss University Hospital**

**Fontana S, Müller U, Perler M, Eberle B, Regli B, Schmidli J, Carrel T, Krummen L, Lädrach A, Mansouri Taleghani B.** Transfusion Medicine and Hemotherapy. 2009;36 (S1):P4.05.

**A case of a fatal hepatitis B virus transfusion transmitted from an erythrocyte concentrate with a very low viral load**

**Stolz M, Weingand T, Maier A, Tinguely C, Gowland P, Wuillemin WA, Niederhauser C.** Transfusion Medicine and Hemotherapy. 2009;36 (S1):P10.01.

**Red blood cell (RBC) use in elective cardiac and vascular surgery: a prospective assessment prior to the implementation of transfusion guidelines in a Swiss university hospital**

**Fontana S, Müller U, Perler M, Staub L, Eberle B, Regli B, Carrel TP, Schmidli J, Schmid P, Mansouri Taleghani B.** Transfusion. 2009.;49(Suppl):166A.

**Effects of a simple guideline for transfusion of red blood cells (RBC) in elective hip and knee replacement on blood supply and costs**

**Fontana S, Müller U, Perler M, Krummen L, Lädrach A, de la Cuadra C, Luginbühl M, Mansouri Taleghani B.** Transfusion. 2009.;49(Suppl):169-170A.

**Screening of Swiss blood donors for an IgA deficiency and its significance for the investigation of anaphylactic transfusion reactions**

**Hustinx H, Scholl N, Gowland P, Krieg R, Stolz M, Fontana S, Niederhauser C.** Schweiz Med Forum. 2009;9 (Suppl.46)

**Requirements to the blood transfusion service in the case of a patient with multiple antibodies including a rare anti-Do<sup>a</sup>**

**Hustinx H, Niederhauser C, Gowland P, Still F, Lovey P, Fontana S.** SMF Swiss Medical Forum. 2009;9(Suppl. 46):P197.

**Line-immunoassay-based differentiation of recent and older HIV-1 infection among all newly diagnosed patients in Switzerland**

Schüpbach J, Niederhauser C, Yerly S, Regenass S, Matter L, Bürgisser P, Gorgievski M, Steffen I, Andreutti C, Schultze D, Martinetti G, Schulze S, Gebhardt M. SÖDAK (Deutsch-Schweiz-Österreichischer AIDS Kongress). 2009;P304.

**Individual nucleic acid testing detects hepatitis B window phase and chronic occult hepatitis in Switzerland: a low endemic region**

Stolz M, Tinguely C, Graziani M, Fontana S, Niederhauser C. Swiss Society for Microbiology: 68<sup>th</sup> Annual Assembly of the SSM. 2009;P107.

**The risk of a second diagnostic window with 4<sup>th</sup> generation HIV assays: two cases**

Niederhauser C, Müller F, Ströhle A, Tinguely C. Swiss Society for Microbiology: 68<sup>th</sup> Annual Assembly of the SSM. 2009;P109.

**Screening of Swiss blood donors for an IgA deficiency and its significance for the investigation of anaphylactic transfusion reactions**

Hustinx H, Scholl N, Gowland P, Krieg R, Stolz M, Fontana S, Niederhauser C. SMF Swiss Medical Forum. 2009;9(Suppl. 46):P174.

**2008**

**Prospective study on red blood cell use in elective cardiac and vascular surgery**

Fontana S, Mansouri Taleghani B, Müller U, Staub L, Eberle B, Regli B, Carrel T-P, Schmidli J, Kwasna M, Schmid P, Lädrach A, Krummen L, de la Cuadra C. Transfusion. 2008.;48(suppl):82A.

**500 ml of blood loss does not decrease non invasive tissue oxygen saturation (StO2) measured by near infrared spectroscopy in healthy adults**

Jeger V, Fontana S, Baur N, Luginbühl M, Ferretti A, Zimmermann H, Exadaktylos A. Biomedical Photonics Network (BMPN). Meeting 2008.

**The JAL(RH48) Antigen in Black and Caucasian Individuals: A Serological and Molecular Study**

Hustinx H, Poole J, Bugert P, Gowland P, Still F, Fontana S, Scharberg EA, Tilley L, Daniels G, Niederhauser C. 2008. Transfusion Medicine. 18; Suppl. 2: 21.

**Molecular RHD Screening of Serological Rh D Negative Swiss Blood Donors**

Niederhauser C, Hustinx H, Gowland P, Still F, Mansouri Taleghani B, Fontana S, Thierbach J, Tissot JD, Maier A. Transfusion Medicine and Hemotherapy. 2008;35(suppl 1):16.

**Individual Nucleic Acid Testing (ID-NAT) in Swiss Blood Donors: A Low Endemic Hepatitis B Virus (HBV) Area**

Niederhauser C, Stolz M, Graziani M, Tinguely C, Fontana S. Transfusion Medicine and Hemotherapy. 2008;35(suppl 1):46.

**Comparison of Iso-Haemolysin and -Agglutinin Testing of Platelet Donors in the Context of the Prevention of Haemolytic Transfusion Reactions**

Schütz A, Kurta V, Hustinx H, Mansouri Taleghani B, Niederhauser C, Fontana S. Transfusion Medicine and Hemotherapy. 2008;35(suppl 1):70.

**Implementation of Transfusion Guidelines for Red Blood Cells (RBC) in Elective Hip and Knee Replacement: A Prospective, Multicenter, Before-and-after Study in 10 Swiss Hospitals**

**Fontana S**, Müller U, Staub L, Luginbühl M, Kwasna M, Schmid P, Krummen L, Lädrach A, de la Cuadra C, **Mansouri Taleghani B**. Transfusion Medicine and Hemotherapy. 2008;35(suppl 1):76-77.

**Red Blood Cell (RBC) Use in Elective Cardiac and Vascular Surgery: A Prospective Assessment Prior to the Implementation of Transfusion Guidelines in a Swiss University Hospital**

**Fontana S**, Müller U, Staub L, Eberle B, Regli B, Carrel T-P, Schmidli J, Kwasna M, Schmid P, **Mansouri Taleghani B**. Transfusion Medicine and Hemotherapy. 2008.;5(suppl 1):77.